October 1, 2012
Today, fool.com health-care analysts Brenton Flynn and David Wiliamson look at Threshold Pharmaceuticals' enormous run so far this year and put the company's recent pullback into a bit of perspective.
David explains what drove these huge returns, points out a few red flags for investors to be aware of, and indicates that this may be a classic market overreaction.
When it comes to do-or-die businesses, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand-new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.